Ex ante prediction of NCT03914651 (300 IU vs 150 IU rFSH starting dose in women aged 35–42 with poor ovarian reserve) from a dose–oocyte–cumulative live birth model

Time-stamped, ex ante prediction of the randomised trial NCT03914651 (Reproductive & Genetic Hospital of CITIC-Xiangya; 300 IU versus 150 IU follitropin alfa starting dose, GnRH antagonist, women aged 35–42 years with AFC ≤ 5 or AMH ≤ 1.2 ng/mL; primary outcome cumulative live birth from the first stimulation). The prediction comes from a dose–oocyte–cumulative live birth model calibrated only on published data. No parameter was fitted to the outcomes of the trial, whose results were not public at deposit. The trial population was anchored on published data from the same centre. Primary prediction (same-centre anchor, γ = 0.09): CLBR 9.3% (150 IU) versus 9.5% (300 IU), a difference of +0.2 points (95% prediction interval for a trial of 130 women per arm: −6.9 to +7.3). Oocytes: 1.66 versus 1.91. A higher starting dose is predicted not to increase cumulative live birth. The record contains the prediction statement, the complete code, a one-command reproduction (reproduce_all.py) and SHA-256 hashes of every file (MANIFEST.json).

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24411685
Primary Topic
Reproductive Health and Technologies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ex ante prediction of NCT03914651 (300 IU vs 150 IU rFSH starting dose in women aged 35–42 with poor ovarian reserve) from a dose–oocyte–cumulative live birth model

Philippe Pinton
Zenodo (CERN European Organization for Nuclear Research)
Reproductive Health and Technologies
article

Ex ante prediction of NCT03914651 (300 IU vs 150 IU rFSH starting dose in women aged 35–42 with poor ovarian reserve) from a dose–oocyte–cumulative live birth model

Philippe Pinton
article en

Abstract

Time-stamped, ex ante prediction of the randomised trial NCT03914651 (Reproductive & Genetic Hospital of CITIC-Xiangya; 300 IU versus 150 IU follitropin alfa starting dose, GnRH antagonist, women aged 35–42 years with AFC ≤ 5 or AMH ≤ 1.2 ng/mL; primary outcome cumulative live birth from the first stimulation). The prediction comes from a dose–oocyte–cumulative live birth model calibrated only on published data. No parameter was fitted to the outcomes of the trial, whose results were not public at deposit. The trial population was anchored on published data from the same centre. Primary prediction (same-centre anchor, γ = 0.09): CLBR 9.3% (150 IU) versus 9.5% (300 IU), a difference of +0.2 points (95% prediction interval for a trial of 130 women per arm: −6.9 to +7.3). Oocytes: 1.66 versus 1.91. A higher starting dose is predicted not to increase cumulative live birth. The record contains the prediction statement, the complete code, a one-command reproduction (reproduce_all.py) and SHA-256 hashes of every file (MANIFEST.json).

Zenodo (CERN European Organization for Nuclear Research)
Reproductive Health and Technologies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon